| Literature DB >> 30082637 |
Chia-Chi Peng1, Chiung-Yao Huang2, Atallah F Ahmed3,4, Tsong-Long Hwang5,6,7, Chang-Feng Dai8, Jyh-Horng Sheu9,10,11.
Abstract
Six new cembranoids, cherbonolides A-E (1⁻5) and bischerbolide peroxide (6), along with one known cembranoid, isosarcophine (7), were isolated from the Formosan soft coral Sarcophyton cherbonnieri. The structures of these compounds were elucidated by detailed spectroscopic analysis and chemical methods. Compound 6 was discovered to be the first example of a molecular skeleton formed from two cembranoids connected by a peroxide group. Compounds 1⁻7 were shown to have the ability of inhibiting the production of superoxide anions and elastase release in N-formyl-methionyl-leucyl-phenyl-alanine/cytochalasin B (fMLF/CB)-induced human neutrophils.Entities:
Keywords: Sarcophyton cherbonnieri; anti-inflammatory activity; biscembranoid peroxide; cembranoid; elastase release inhibition
Mesh:
Substances:
Year: 2018 PMID: 30082637 PMCID: PMC6117711 DOI: 10.3390/md16080276
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Cembranoid isolated from Sarcophyton cherbonnieri.
Figure 2Selected 1H-1H COSY and HMBC correlations of 1, 2 and 3−5.
Figure 3Key NOESY correlations of 1.
Figure 41H NMR chemical shift differences Δδ (δS − δR) in ppm for the MTPA esters of 1 and 3.
1H and 13C NMR chemical shifts for compounds 1–4.
| Position | 1 | 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|---|---|
| δH, m ( | δC
| δH, m ( | δC
| δH, m ( | δC
| δH, m ( | δC
| |
| 1 | 160.7, C | 160.6, C | 160.6, C | 159.8, C | ||||
| 2 | 5.44, dd | 77.8, CH | 5.43, dd | 77.8, CH | 4.91, dd | 78.4, CH | 4.98, d | 77.8, CH |
| 3 | 4.90, d | 122.2, CH | 4.91, d | 122.7, CH | 4.55, d | 123.9, CH | 4.45, d | 123.5, CH |
| 4 | 141.6, C | 140.8, C | 140.2, C | 139.4, C | ||||
| 5 | 2.20, m | 47.9, CH2 | 2.18, dd | 42.6, CH2 | 2.42, dd | 49.1, CH2 | 1.98, m | 49.3, CH2 |
| 5 | 2.76, dd | 2.87, dd | 189, m | 2.25, dd | ||||
| 6 | 4.70, ddd | 65.2, CH | 4.97, ddd | 78.3, CH | 3.84, dd | 69.6, CH | 4.21, ddd | 64.8, CH |
| 7 | 5.20, d (10.4) | 128.1, CH | 5.05, d (9.2) | 123.1, CH | 5.09, d (9.2) | 131.6, CH | 4.84, d (9.2) | 131.2, CH |
| 8 | 139.8, C | 144.2, C | 138.4, C | 139.4, C | ||||
| 9 | 2.03, m | 36.8, CH2 | 2.07, m | 36.9, CH2 | 2.21, ddd | 28.2, CH2 | 1.58, m | 28.5, CH2 |
| 9 | 2.38, m | 2.42, m | 1.63, m | 2.30, dd | ||||
| 10 | 1.29, m | 23.5, CH2 | 1.35, m | 23.6, CH2 | 1.16, m | 23.9, CH2 | 1.60, m | 22.7, CH2 |
| 10 | 2.51, m | 2.17, m | 1.84, m | 1.28, m | ||||
| 11 | 2.42, dd | 61.4, CH | 2.43, m | 61.4, CH | 2.24, dd | 58.9, CH | 1.98, m | 62.6, CH |
| 12 | 60.8, C | 60.8, C | 59.7, CH | 60.9, C | ||||
| 13 | 2.03, m | 36.9, CH2 | 2.02, m | 37.0, CH2 | 1.49, m | 35.5, CH2 | 1.61, m | 37.1, CH2 |
| 13 | 1.06, m | 1.07, m | 0.98, m | 0.65, m | ||||
| 14 | 2.49, m | 23.7, CH2 | 2.52, m | 23.7, CH2 | 1.58, m | 22.2, CH2 | 2.08, m | 23.1, CH2 |
| 14 | 2.01, m | 2.03, m | 1.58, m | 1.65, m | ||||
| 15 | 123.8, C | 123.8, C | 123.8, C | 123.7, C | ||||
| 16 | 174.4, C | 174.4, C | 173.9, C | 174.3, C | ||||
| 17 | 1.86, s | 8.8, CH3 | 1.86, s | 8.7, CH3 | 1.64, s | 8.8, CH3 | 1.63, s | 8.8, CH3 |
| 18 | 1.70, s | 15.9, CH3 | 1.72, s | 15.9, CH3 | 1.31, s | 18.1, CH3 | 1.28, s | 16.9, CH3 |
| 19 | 1.86, s | 14.9, CH3 | 1.89, s | 15.3, CH3 | 1.45, s | 22.2, CH3 | 1.32, s | 21.8, CH3 |
| 20 | 1.33, s | 15.8, CH3 | 1.33, s | 15.8, CH3 | 1.00, s | 17.1, CH3 | 0.99, s | 16.4, CH3 |
| 6-OOH | 7.99, br s | |||||||
Spectrum recorded at 400 MHz in CDCl3. Spectrum recorded at 100 MHz in CDCl3. Spectrum recorded at 400 MHz in C6D6. Spectrum recorded at 100 MHz in C6D6.
Figure 5Key NOESY correlations for 3 and 4.
1H and 13C NMR chemical shifts for compounds 5 and 6.
| Position | 5 | 6 | |||||
|---|---|---|---|---|---|---|---|
| δH, m ( | δC
| δH, m ( | δC
| δH, m ( | δC
| ||
| 1 | 160.4, C | 141.4, C | 1′ | 141.5, C | |||
| 2 | 4.95, d (10.0) | 78.4, CH | 5.28, d (10.0) | 82.7, CH | 2′ | 5.50, d (10.0) | 81.9, CH |
| 3 | 4.42, d (10.0) | 124.6, CH | 5.06, d (10.0) | 126.4, CH | 3′ | 4.92, d (10.0) | 125.1, CH |
| 4 | 139.2, C | 140.2, C | 4′ | 141.0, C | |||
| 5 | 1.95, m | 44.6, CH2 | 2.21, m | 38.5, CH2 | 5′ | 2.21, m | 38.8, CH2 |
| 5 | 2.47, br d (11.0) | 2.32, m | 5′ | 2.31, m | |||
| 6 | 4.58, ddd (11.0, 9.5, 2.5) | 78.9, CH | 24.2, CH2 | 6′ | 24.2, CH2 | ||
| 6 | 2.07, m | 6′ | 2.07, m | ||||
| 6 | 2.42, m | 6′ | 2.42, m | ||||
| 7 | 4.78, d (9.5) | 126.6, CH | 4.98, dd (9.2, 9.2) | 125.6, CH | 7′ | 4.95, dd (9.2, 9.2) | 125.5, CH |
| 8 | 143.8, C | 133.1, C | 8′ | 133.3, C | |||
| 9 | 1.65, m | 29.8, CH2 | 1.96, m | 36.6, CH2 | 9′ | 1.96, m | 36.6, CH2 |
| 9 | 2.52, dd (14.0, 4.5) | 2.27, m | 9′ | 2.27, m | |||
| 10 | 1.28, m | 23.4, CH2 | 1.22, m | 23.6, CH2 | 10′ | 1.22, m | 23.7, CH2 |
| 10 | 1.62, m | 2.04, m | 10′ | 2.04, m | |||
| 11 | 1.97, m | 63.3, CH | 2.51, m | 62.1, CH | 11′ | 2.51, m | 62.2, CH |
| 12 | 61.5, C | 61.2, CH | 12′ | 61.3, C | |||
| 13 | 1.59, m | 37.6, CH2 | 1.83, m | 37.3, CH2 | 13′ | 1.83, m | 37.4, CH2 |
| 13 | 0.64, m | 0.95, m | 13′ | 0.95, m | |||
| 14 | 2.07, m | 23.7, CH2 | 2.33, m | 22.6, CH2 | 14′ | 2.33, m | 22.7, CH2 |
| 14 | 1.61, m | 1.81, m | 14′ | 1.81, m | |||
| 15 | 124.3, C | 124.9, C | 15′ | 124.9, C | |||
| 16 | 174.3, C | 6.13, br s | 114.3, C | 16′ | 6.17, d (3.6) | 114.4, CH | |
| 17 | 1.63, s | 9.4, CH3 | 1.72, s | 10.2, CH3 | 17′ | 1.73, s | 10.2, CH3 |
| 18 | 1.29, s | 17.3, CH3 | 1.58, s | 14.6, CH3 | 18′ | 1.59, s | 14.6, CH3 |
| 19 | 1.34, s | 22.5, CH3 | 1.65, s | 14.7, CH3 | 19′ | 1.65, s | 14.7, CH3 |
| 20 | 0.98, s | 16.9, CH3 | 1.27, s | 15.7, CH3 | 20′ | 1.27, s | 15.7, CH3 |
| 6-OOH | 7.25, br s | ||||||
Spectrum recorded at 500 MHz in C6D6. Spectrum recorded at 125 MHz in C6D6. Spectrum recorded at 400 MHz in CDCl3. Spectrum recorded at 100 MHz in CDCl3.
Figure 6Selected 1H-1H COSY and HMBC correlations of 6.
Figure 7ESIMS fragmentation of 6.
Figure 8Selected NOESY correlations for 6.
Selected 1H and 13C NMR data comparison with 6, (2S,11R,12R)-isosarcophytoxide (8) and (2R,11R,12R)-isosarcophytoxide (9).
| Position | 6 | 8 | 9 |
|---|---|---|---|
| H-11 | δH 2.51 (H-11, H-11′) | δH 2.50 | δH 2.75 |
| C-11 | δC 62.1 (C-11) | δC 62.3 | δC 61.2 |
| δC 62.2 (C-11′) | |||
| C-12 | δC 61.2 (C-12) | δC 61.4 | δC 60.7 |
| δC 61.3 (C-12′) | |||
| C-13 | δC 37.3 (C-13) | δC 37.4 | δC 35.4 |
| δC 37.4 (C-13′) | |||
| C-14 | δC 22.6 (C-14) | δC 22.5 | δC 20.4 |
| δC 22.7 (C-14′) | |||
| H3-18 | δH 1.58 (H3-18) | δH 1.58 | δH 1.70 |
| δH 1.59 (H3-18′) | |||
| H3-20 | δH 1.27 (H3-20, H3-20′) | δH 1.28 | δH 1.18 |
| C-20 | δC 15.7 (C-20, C-20′) | δC 15.7 | δC 17.7 |
The selected 1H and 13C data were cited from ref. [36,37].
Figure 9Structures of (2S,11R,12R)-isosarcophytoxide (8) and (2R,11R,12R)-isosarcophytoxide (9) [36].
Scheme 1Proposed biosynthetic pathway for 6.
Inhibitory effects of compounds 1–7 on superoxide anion generation and elastase release in fMLF/CB-induced human neutrophils.
| Compounds | Superoxide Anion | Elastase Release | |
|---|---|---|---|
| IC50 (μM) a | Inh b % | Inh b % | |
| >30 | 32.1 ± 4.3 ** | 37.6 ± 5.0 ** | |
| >30 | 4.0 ± 6.7 | 23.5 ± 6.6 * | |
| >30 | 44.5 ± 4.6 *** | 35.6 ± 6.2 ** | |
| >30 | 6.4 ± 4.2 | 27.6 ± 6.4 ** | |
| >30 | 2.6 ± 6.2 | 30.5 ± 4.6 ** | |
| 26.2 ± 1.0 | 64.6 ± 0.8 *** | 42.4 ± 5.1 ** | |
| >30 | 3.5 ± 5.3 | 20.7 ± 4.1 ** | |
| Idelalisib | 0.07 ± 0.01 | 102.8 ± 2.2 *** | 99.6 ± 4.2 |
a Concentration necessary for 50% inhibition (IC50). b Percentage of inhibition (Inh %) at 30 μM. Data are presented as mean ± S.E.M. (n = 3–4); * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control value.